肝病患者肿瘤标志物检测的临床意义  

Assaied Clinical Signification of the Tumour Mark Substances in Hepatic Diseases

作　　者：廖胜东[1] 杨昭徐[1] 朱玉群[1] 善若明[2] 

机构地区：[1]首都医科大学附属北京天坛医院,100050 [2]首都医科大学临床检测中心

出　　处：《中西医结合肝病杂志》1998年第3期139-141,共3页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

摘　　要：探讨肝病患者各项肿瘤标志物的变化规律及临床意义。方法:对236例各型肝病患者进行血清α-L-岩藻糖苷酶、甲胎蛋白、癌胚抗原、糖类抗原50、β_2-微球蛋白、降钙素、铁蛋白的联合检测。结果:各型肝炎上述指标有不同程度升高。结论:各型肝病检测值的变化与肝病病情呈平行关系,不同程度反应了肝脏的受损程度,对各型肝病的鉴别诊断能有所帮助,对原发性肝癌联合检测总阳性率高于各单项检测。Aim: To study clinical signification of the tumour mark substances in hepatic diseases. Method:236 patients with liver diseases were examined:serum α-L-fucosidase(AFU),carbohydrate antigen 50 (CA50), alpha fetoprotein (AFP), carcinoemberyonic antigen (CEA),β2-mi-croglobulin (βb2-MG), calcitonine (CT), ferritin (SF). Result: The determination level of the tumour mark substances are higher in several hepatic disease. Conclusion: The changes level reflect the degree of suffer injury in several hepatic disease. Positive reaction of unite assay are higher than sin-ele assay in cancer of the liver.

关 键 词：肝病 肿瘤标志物 检测 

分 类 号：R575[医药卫生—消化系统]